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Abstract
The genome of human immunodeficiency virus type 1 (HIV-1) encodes 15 distinct proteins, three of which provide essential enzymatic functions:
a reverse transcriptase (RT), an integrase (IN), and a protease (PR). Since these enzymes are all homodimers, pseudohomodimers or multimers,
disruption of protein–protein interactions in these retroviral enzymes may constitute an alternative way to achieve HIV-1 inhibition. A growing
number of dimerization inhibitors for these enzymes is being reported. This mini review summarizes some approaches that have been followed for
the development of compounds that inhibit those three enzymes by interfering with the dimerization interfaces between the enzyme subunits.
© 2006 Elsevier B.V. All rights reserved.
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. Introduction
Acquired immunodeficiency syndrome (AIDS), caused by
uman immunodeficiency virus infection, is still one of the most
mportant challenges for the chemotherapy of the early 21st cen-
ury. HIV has killed more than 25 million people since it was
rst recognized in 1981. Despite the great efforts that are being
evoted to prevent, treat and to better understand the disease,
his is one of the main causes of morbidity and mortality world-
ide, with different incidence in developing and non-developing
ountries. The number of drugs against this disease is slowly
∗ Corresponding author. Tel.: +34 915622900; fax: +34 915644853.
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ncreasing but the chemotherapy is far from being solved. The
equired long-term treatments are accompanied by adverse side
ffects, lack or difficulties in compliance with the arduous treat-
ent protocols, and resistance development, which in turn may
ead to the halt of the clinical treatment. This indicates that the
armamentarium” for the clinical treatment of HIV infection is
ot enough to control either viral replication or the appearance
f viral resistant strains. Therefore, there is an urgent need for
he development of new and safer drugs, active against the cur-
ently resistant viral strains or directed to novel targets in the
iral replicative cycle, which may be useful for multiple drug
ombination.
The design of drugs directed against enzymes involved in
athological processes is a realistic and one of the most effi-
acious therapeutic options. Many of the top 100 drugs sold
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Fig. 1. Ribbon representation of HIV-1 protease (left), reverse transcriptase (middle), and integrase (right) displayed using molecular graphics program PyMol
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he dimerization interactions (For interpretation of the references to color in thi
orldwide are enzyme inhibitors. While searching for novel
ore specific enzyme inhibitors, many efforts are being directed
owadays to inhibition modalities that are different from the
nteraction at the substrate-binding site (active site). In particu-
ar, small-molecule inhibitors of protein–protein interactions are
eceiving a great deal of attention (Keskin et al., 2005; Loregian
t al., 2002; Loregian and Palu`, 2005; Pommier and Cherfils,
005; Toogood, 2002). This approach increases our understand-
ng of the basic biological processes where the target enzymes
re involved (ranging from intercellular communication to pro-
rammed cell death) and at the same time generates great oppor-
unities for the identification of novel pharmaceuticals that can
ffer attractive opportunities for therapeutic intervention. Till
ery recently, it has been considered that protein–protein inter-
ctions were the result of the sum of numerous low energy point
nteractions. However, it is now commonly accepted that just a
ew of these contributions are crucial for the protein–protein
nteraction, that is, a significant contribution to the binding
nergy is localized in small regions that are designated as “hot
pots” (Keskin et al., 2005). Nowadays it is accepted that small
olecules are able to inhibit protein–protein interactions, and
ome examples of these kinds of inhibitors are used in the clinic
Jordan, 2002; Ockey and Gadek, 2002; Pommier and Cherfils,
005; Toogood, 2002). Since these ligands do not need to be
tructurally related to substrates they could lead to safer and
ore efficacious drugs by overcoming selectivity issues and sub-
trate competition issues.
The genome of human immunodeficiency virus type 1 (HIV-
) encodes 15 distinct proteins (Frankel and Young, 1998), three
f which provide essential enzymatic functions: a reverse tran-
criptase (RT), an integrase (IN), and a protease (PR). These
hree enzymes are all homodimers or pseudohomodimers. Due
o the structural information available for HIV, and the impor-
ance of these enzymes for viral replication, a growing number
f dimerization inhibitors for these enzymes is being reported.
herefore, disruption of protein–protein interactions in retrovi-al enzymes may constitute an alternative way to achieve HIV-1
nhibition.
This mini review summarizes some approaches that have
een followed for the development of compounds that inhibit
b
1
pt-accessible surface that has been colored in either magenta or blue to highlight
re legend, the reader is referred to the web version of the article.).
hese enzymes by interfering with the dimerization interfaces
etween the enzyme subunits (Fig. 1).
. HIV-1 reverse transcriptase (dimerization inhibitors
f HIV-1 RT)
HIV-1 RT catalyzes an essential step in the replication of
IV-1, namely the synthesis of double-stranded DNA from the
etroviral RNA genome. The biologically active form of the
nzyme is an asymmetric heterodimer composed of two subunits
f identical sequence named p66 and p51. The monomers are
atalytically inert. The p66 subunit contains the catalytic site (a
riad of aspartic acid residues) and both polymerase and RNase
activities, whereas the shorter p51 subunit lacks these func-
ions but provides structural support to the p66 subunit. In fact,
51 has an impact on the catalytic activity of the enzyme (Divita
t al., 1995) because it is essential for loading the p66 subunit
n the template primer (Harris et al., 1998). For the process
f native dimerization between p66 and p51 a two-step model
as been proposed (Basu et al., 1992). The first step involves a
oncentration-dependent association of both subunits (p66 and
51) resulting in an inactive intermediate, which slowly iso-
erizes to the “mature” heterodimeric form of the enzyme in a
econd step (Divita et al., 1993). The dimerization is essential for
fully functional RT. The dimeric form of the enzyme is an abso-
ute requirement for all enzymatic activities (Mu¨ller et al., 1989;
estle et al., 1990, 1992). Therefore, dimerization is essential
or a fully functional RT (Restle et al., 1990) and this process
ffers an excellent opportunity to inhibit the enzyme by a differ-
nt mechanism from those described so far, that is, by disrupting
key protein–protein interaction. Among the advantages of this
ind of inhibitors are an expected higher specificity and a lower
isk of selection of drug-resistant strains, since mutations at the
66–p51 interface will hamper the association process and thus
ay compromise the catalytic activity of the enzyme (Auwerx
t al., 2005a,b; Balzarini et al., 2005).
There are three major contact areas in the dimer interface
etween the p66 and p51 subunits (Becerra et al., 1991) in HIV-
RT, namely the fingers subdomain of p51 with the palm of
66, the connection subdomains of both subunits, and the thumb
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omain of p51 with the RNase H domain of p66 (Kohlstaedt et
l., 1992; Huang et al., 1998). The most intensively studied inter-
ace area between p66 and p51 is the tryptophan-rich amino acid
tretch in the connection subdomain of both RT subunits, con-
isting of six tryptophan residues at codons 398, 401, 402, 406,
10, and 414 (which are highly conserved amongst all primate
entiviral RTs). These amino acids play an important role in RT
imerization (Harris et al., 1998; Mu¨ller et al., 1989), mediated
ainly through the p66 subunit.
The first attempts to develop dimerization inhibitors of HIV-1
T consisted on the synthesis of peptides mimicking the major
ontacts between the p66 and p51 subunits, in order to pre-
ent heterodimer formation (Baillon et al., 1991; Divita et al.,
993). Thus, synthetic tryptophan-rich peptides of 19 and 10
esidues derived from a sequence within the tryptophan-rich
mino acid stretch (positions 384–407) were inhibitors of HIV-1
T dimerization (Divita et al., 1994, 1995; Morris et al., 1999;
estle et al., 1990). The decapeptide was shown to interact
referentially with the p51 subunit of the heterodimeric HIV-1
T, in a cleft between the fingers and the connection subdo-
ains of p51 that contains the two highly conserved Phe61
nd Trp24 residues (Depollier et al., 2005). As a consequence,
he peptide destabilizes the dimer conformation and triggers
issociation.
Another motif is suggested to be involved in RT dimerization.
T is a central region that contains the leucine hepta-repeat motif
Leu282–Leu310) in the p66 subunit (Becerra et al., 1991; Goel
t al., 1993).
Finally, a third important region of the p66/p51 dimer inter-
ace is the 7–8 loop in p51 that forms the “floor” of the
on-nucleoside reverse transcriptase inhibitor (NNRTI) bind-
ng pocket and fits in a groove-like structure that constitutes the
emplate/primer binding site in the p66 subunit (Restle et al.,
990; Harris et al., 1998). This loop of the p51 subunit is essen-
ial for the catalytic function on the p66 subunit (Pandey et al.,
001, 2002), and its presence is an absolute requirement for RT
imerization (Pandey et al., 2002).
With respect to the interaction of drugs at the p66–p51 dimer
nterface, it is noteworthy that exposure of HIV-1 RT with TSAO
olecules (whose prototype compound is the thymine deriva-
ive, TSAO-T (1), a peculiar family of non-nucleoside reverse
ranscriptase inhibitors developed by our group in collabora-
ion with the group of Drs. Jan Balzarini and Erik De Clercq at
he Rega Institute of Leuven (Belgium) (Balzarini et al., 1992;
amarasa et al., 1992, 2004), has been shown to destabilize
he heterodimeric RT leading to a loss in its ability to bind DNA
Sluis-Cremer et al., 2000). Remarkably, this effect has not been
bserved with any other NNRTI. Thus, TSAO-T represents the
rst example of a small non-peptidic molecule able to interfere
ith the dimerization process of HIV-1 RT (Sluis-Cremer et al.,
000).
In the absence of experimentally solved crystallographic
tructures, computational docking studies led us to propose a
inding mode for TSAO derivatives with HIV-1 RT (Rodrı´guez-
arrios et al., 2001) distinct from that of “classical” NNRTIs.
ccording to this model, TSAO derivatives make extensive use
f the 7/8 loop of the p51 subunit, which is consistent with
P
t
o
tesearch 71 (2006) 260–267
he fact that site-directed mutagenesis and resistance studies
ave shown that this glutamic acid residue is the key interac-
ion point for TSAO binding (Boyer et al., 1994; Jonckheere
t al., 1994). Moreover, the 7–8 loop of the p51 subunit
as computationally identified as a “hot spot” for dimeriza-
ion (Rodrı´guez-Barrios et al., 2001) strongly suggesting that
t may constitute by itself a novel pharmacological target for
T inhibition. Indeed, recent studies have provided experimen-
al evidence that this loop in the p51 subunit is essential for
T dimerization and catalytic efficiency of the p66 subunit
Auwerx et al., 2005a,b; Balzarini et al., 2005; Pandey et al.,
002).
According to the proposed mode of binding to HIV-1 RT
or TSAO derivatives (Rodrı´guez-Barrios et al., 2001), the most
uried part of the molecule is the spiroaminosultone moiety,
hile the substituents on the N-3 position of the thymine base
re relatively exposed and they run parallel to the subunit inter-
ace. For these reasons, we considered chemical modifications
t these two positions in the prototype compound, TSAO-T, as
he most crucial to study the possible impact on RT dimeriza-
ion. In addition, to improve the interactions with neighbouring
mino acids from both subunits, different functional groups
ere introduced at position 3′′ of the spiro ring (Lobato´n et
l., 2002). In general, the compounds showed pronounced anti-
IV-1 activity, although lower than that of TSAO-T and they
lso turned out to be much more toxic. Studies on the effect of
hese 3′′-TSAO modified compounds on RT dimerization indi-
ate that compound 2 seems to have a higher destabilizing effect
imerization than TSAO-T (unpublished results). In the series of
SAO compounds bearing different carbonyl functionalities at
he 4′′-position (de Castro et al., 2005), many analogues showed
igh anti-HIV-1 activity against viral replication, but these 4′′-
SAO modified compounds did not show any improvement
ver the parent TSAO-T as dimerization inhibitors (unpublished
esults). On the other hand, substitutions at the N-3 position
f the thymine base led to compounds endowed with a greater
mpact on RT dimerization (Bonache et al., 2005) suggesting
hat interactions with one or more of the dimer interface residues
lose to the TSAO binding site (Glu138) may help destabilize
he RT dimer by disrupting key interface interactions.
Virtually all synthesized N-3-substituted TSAO derivatives
howed marked anti-HIV-1 activities (in the nanomolar range).
he best compounds (EC50 = 10–30 nM) were those bearing at
-3 an alcohol (3) or N-methylcarboxamide (4) groups. The
-3 methylcarboxamide TSAO derivative 4 showed a supe-
ior effect on HIV-RT dimerization than TSAO-T (unpublished
esults). To explain the increased activity of 3 and 4 the N-3-
ubstituted compounds were docked into our proposed binding
ite at the p66–p51 dimer interface (Rodrı´guez-Barrios et al.,
001). According to the docking model, the improved activ-
ty of compound 3 could be explained by the establishment of
n additional hydrogen bond between the attached (CH2)3–OH
roup at the N-3 position of TSAO-T and the carbonyl group of
ro-B140 in the p51 subunit of the enzyme. On the other hand,
he resulting model showed the N-3 methyl carboxamide moiety
f 4 running parallel to the subunit interface could likewise form
wo hydrogen bonds with the enzyme (Bonache et al., 2005), one
M.-J. Camarasa et al. / Antiviral R
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pig. 2. Examples of TSAO derivatives and structure of BBNH (HIV-1 RT dimer-
zation inhibitors).
etween the amide nitrogen of 4 and the main-chain carbonyl
xygen of Pro-B140 and a second one between the amide car-
onyl and the terminal amino group of the side chain of Lys-B49.
he additional stabilization gained from these extra interactions
ight explain why 4 turns out to be a 6-fold better inhibitor
han TSAO-m3T. This outcome is fully consistent with the pre-
iction that additional interactions at or near the p51–p66 inter-
ace could result in compounds with improved binding affinity
ver the prototype TSAO-T (Rodrı´guez-Barrios et al., 2001)
Fig. 2).
Regarding other small molecules that seem to have some
mpact on HIV-1 RT dimerization, BBNH (5), a multitarget
nhibitor of HIV-1 RT (Arion et al., 2002; Borkow et al., 1997),
as also found to decrease the dimeric stability of RT (Sluis-
remer et al., 2002). On the other hand, it has recently been
eported that several NNRTIs enhance enzyme dimerization
Sluis-Cremer et al., 2000, 2002; Sluis-Cremer and Tachedjian,
002; Tachedjian and Goff, 2003; Tachedjian et al., 2001).
. HIV-1 integrase (dimerization inhibitors of HIV-1
ntegrase)
HIV integrase catalyzes the insertion and integration of viral
NA into the host genome. This essential enzyme, which is
equired for viral replication, has no counterpart in the host cell.
he structure and function of HIV-1 integrase have been recently
eviewed (Asante-Appiah and Skalka, 1999; Chiu and Davies,
004; Pommier and Cherfils, 2005). HIV-1 IN is a 32 kDa protein
hat comprises three independently folded domains (Engelman
nd Craigie, 1992; Engelman et al., 1993; Katzman and Sudol,
995), the N-terminal domain (residues 1–50) characterized by
conserved HHCC zinc binding motif (Cai et al., 1997), theimeric catalytic core domain (residues 50–212) and the C-
erminal domain (residues 213–288), involved in non-specific
NA binding (Lutzke and Plasterk, 1998). Up to now structure
f the whole integrase is not available. Structural and functional
t
g
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tudies show that individual functional domains or two-domains
N molecules form dimers themselves. However, in vivo and in
itro complementation studies suggest that the active HIV IN is
multimer (at least a tetramer) (Engelman et al., 1993; Esposito
nd Craigie, 1999; Wang et al., 2001). Moreover, the current
esults suggest that the whole integrase might be a homodimer.
he dimerization interface is made of four helices (1,3,5,
6) and one  strand (3) from each monomer in the catalytic
ore domain and is stabilized by additional subunit interface
nteractions (residues 29–35 from the N-terminal domain) in
he N-terminal catalytic core (Chen et al., 2000; Sluis-Cremer
nd Tachedjian, 2002).
Peptide-based inhibitors derived from the dimeric interface
f the HIV-1 IN enzyme, have been designed and synthesized
Lutzke et al., 1995). Thus, Sourgen et al. (1996) described two
ynthetic peptides containing the residues 147–175 of the HIV-
IN, and the same sequence but with Lys159 replaced by a
roline. Only the first one showed an in vitro inhibitory effect
n strand transfer, 3′ processing and autointegration activities.
owever, it is not clear whether this activity is due to interfer-
nce with the dimerization interface of integrase. Maroun et al.
2001) described peptides INH1 (which mimics the amino acid
equence of 1 helix, 17 residues from amino acids 93–107)
nd INH5 (which incorporates the 5 helix and part of the loop
eparating the 4 and 5 helices, 21 residues from amino acids
67–187), both derived from the sequences of the 1 and 5
elices of the catalytic core. These peptides inhibited the strand
ransfer activity of the enzyme with IC50 values in the nM range,
eing INH5 a better inhibitor than INH1. Both peptides per-
urbed the association–dissociation equilibrium of the whole
nzyme and catalytic cores. Zhao et al. (2003) synthesized five
nterfacial peptides derived from the dimeric interface of HIV-1
N. The peptide sequences correspond to the five regions of the
atalytic domain (1, 3, 5, 6, and 3). All peptides were
ound to adopt a random coil conformation in aqueous solution,
s assessed by circular dichroism. Three peptides (1, 5, and
6) were inhibitors of 3′-endonuclease activity of the enzyme,
ith IC50 values in the M range and were able to disrupt the
rosslinking of the IN dimer.
Indolicidin, a natural antimicrobial peptide, was found to
ave IN inhibitory activity. Further analogues of indolicidin
ith short peptidic sequences (hexapeptides) showed improved
ctivity (Robinson et al., 1998). Krajewski et al. (2003, 2004)
repared dimers and tetramers by connecting the monomers’ C-
erminal ends using different linkers. The tetramers proved to be
ore potent than dimeric peptides in both 3′-end processing and
trand transfer assays. These peptides seem to act as multimeric
nhibitors that bind simultaneously to two or four neighbouring
atalytic sites within the integrase oligomeric complex.
. HIV-1 protease (dimerization inhibitors of HIV-1
rotease)HIV-1 protease is the enzyme responsible for the post-
ranslational processing of viral polyproteins and subsequent
eneration of the structural and functional proteins essential for
iral replication (Oroszlan and Luftig, 1990).
2 iral R
a
(
e
T
t
a
a
f
e
m
a
1
a
i
i
A
b
r
m
a
t
i
a
a
t
o
m
t
a
c
h
s
t
a
e
t
t
t
a
f
(
t
t
a
a
t
g
D
s
e
5
t
P
a
g
C
h
4
t
i
n
p64 M.-J. Camarasa et al. / Antiv
The fact that this step is essential for maturation of the virus
nd production of infectious particles accounts for the early
Huff, 1991; Wlodawer and Erickson, 1993) and current inter-
st (Gago, 1999; Lebon and LeClecq, 2000; Priestle et al., 1995;
omasselli and Heinrikson, 2000) in HIV protease as a prime
arget for antiretroviral drug design. HIV PR is a homodimeric
spartyl protease with each monomer having 99 residues. The
ctive site is located at the bottom of a cavity in the dimer inter-
ace and is covered by two -hairpins, called “flaps”, one from
ach monomer that are very flexible (Wlodawer et al., 1989),
ost likely to facilitate substrate binding and product release,
nd participate in the binding of inhibitors (Nicholson et al.,
995). Since each monomer contributes one of the two cat-
lytic aspartic acid residues (Asp25) the monomers are catalyt-
cally inert and dissociation of the enzyme homodimer results
n a complete loss of catalytic activity. Each active site triad
sp25–Thr26–Gly27 is located in a loop whose structure is sta-
ilized by a “firearm’s grip” network of hydrogen bonds. As a
esult, the carboxylic groups of Asp25 from both subunits, which
ay have different ionization states depending on whether or not
n inhibitor is bound to the enzyme (Smith et al., 1996), are posi-
ioned very close together and in a nearly coplanar arrangement.
The homodimeric nature of HIV-1PR suggests that enzyme
nhibition could be accomplished by preventing the self-
ssembly of the biologically active dimer in infected cells as
n alternative to the use of substrate analogues. A large part of
he dimerization interface (a four stranded -sheet) is made up
f an interdigitation of the N- and C-terminal portions of each
onomer (residues 1–4 and 96–99). Since this region appears
o be highly conserved among HIV-1 isolates, it stands out as an
ttractive target that is quite distinct from the substrate-binding
avity. In fact, the proof of concept for the feasibility of this
ypothesis was obtained as early as 1991 when peptides corre-
ponding to the N- and C-termini of HIVp were shown to effec-
ively inhibit enzyme activity (Schramm et al., 1991; Zhang et
b
a
A
g
Fig. 3. Examples of compounds reported to be able to prevent HIesearch 71 (2006) 260–267
l., 1991), albeit at micromolar concentrations. In one of the first
xamples of dissociative inhibition, kinetic analysis showed that
he tetrapeptide Ac–Thr–Leu–Asn–Phe–COOH, corresponding
o the COOH-terminal segment of the enzyme, was able to bind
o the inactive protomers and prevent their association into the
ctive dimer (Sluis-Cremer and Tachedjian, 2002). Further inter-
erence with dimer assembly has been achieved, among others
Babe´ et al., 1992), by contiguous peptide sequences containing
he N- and C-terminal regions of HIV PR linked with a 3.5 A˚
ether composed of three glycine residues (Zutshi et al., 1997)
nd by covalently crosslinked N-terminal HIVp peptides (Park
nd Raines, 2000).
Peptides with affinity for the interfacial surface of HIV pro-
eases constituent monomers have been sought also using a
enetic selection approach. By fusing a non-catalytically active
25N HIV PR variant to the DNA-binding domain of the repres-
or protein from bacteriophage , a hybrid repressor was gen-
rated that allowed high-throughput screening of a library of
× 108 peptides with nine random amino acid residues. Less
han one peptide in 106 was found to be able to disrupt HIV
R monomer association and in those identified there was an
bundance of non-polar residues, especially valine, alanine, and
lycine (Fan et al., 1998). Addition of a cysteine residue to the
-terminus of one of these peptides and crosslinking with the
omobifunctional reagent 1,6-hexane-bis-vinylsulfone, led to a
0-fold more potent dissociative inhibitor (dissociative inhibi-
ion constant of 0.8M) (Fig. 3).
Similar low-micromolar, non-competitive or dissociative
nhibition constants have been reported for a few non-peptidic
atural products and derivatives, most significantly some triter-
enes (e.g. ursolic acid) identified through a pharmacophore-
ased computer search of the Cambridge Structural Database,
nd several simplified pentaester derivatives of didemnaketals
and B (first isolated from a marine ascidian belonging to the
enus Didemnum) (Fan et al., 1998).
V PR monomer association or promote dimer dissociation.
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Irreversible inhibitors of HIV PR have been also described.
hus, an interface binding peptide able to form a disulfide bond
ith Cys95, present at the dimerization interface of HIV-1 PR
Zutshi and Chmielewski, 2000) proved to be a potent cross-
inking inhibitor of HIV-1 protease (Kinac of 3.7M).
As described here so far, strategies for developing new
nhibitors using interfacial peptides derived from the N- or
-terminal segments have been applied successfully in sev-
ral studies (Schramm et al., 1991, 1993, 1996). This work
uggests that short peptides derived from these segments are
ble to interrupt homodimer formation by non-covalent disso-
iative inhibition. Covalently cross-linked interfacial peptides
rom each N- and C-terminus of the protease designed to bridge
wo peptide chains using flexible tether molecules, inhibited
rotease activity and decreased the amount of protease dimer
n solution (Schramm et al., 1996; Hwang and Chmielewski,
004). Bouras et al. (1999) introduced a more rigid scaffold
n the tether (to increase the conformational constrain), called
molecular tongs” such as resorcinol, 2,6-pyridinediol and 2,7-
aphthalenediol, leading compounds active in the micro and
ubmicromalor range. Merabet et al. (2004) introduced “new
olecular tongs” based on quinoline and naphtalene scaffolds
inked to two peptidic strands of different sequence. Some
f the compounds prepared acted as dimerization inhibitors
t submicromolar concentrations. Song et al. (2001) intro-
uced new conformationally constrained templates such as a
-sheet nucleator” that connects the interfacial N- and C-
erminal peptide fragments from the protease sequence and
n “unnatural -strand mimetic”, which interferes with the -
heet interaction between two monomers and inhibits enzymatic
ctivity.
Dimerization inhibitors of HIV-1 PR based on a chiral
ipophilic bicyclic guanidinium subunit as the central tether
etween a short peptide mimicking the C-terminal native strand,
o interact with both C and N termini of the monomer, and an
dditional hydrophobic bulky group (TBDPS, Cholesteryl) tar-
eting the dimer interface have also been described (Breccia
t al., 2003). Some of the compounds described inhib-
ted the dimerization of HIV PR in the nanomolar range
Kid = 150–400 nM).
. Conclusions
The field of interfacial binding inhibitors for fighting against
IV is still in its infancy but new techniques are being devel-
ped that will hopefully provide some guidelines for the design
f novel drug candidates. This approach is clearly more chal-
enging than others aimed at identifying ligands that will bind
o preorganized small pockets meant for binding natural small
olecules but the outcome of these efforts can be highly reward-
ng. The three protein–protein interfaces present in RT, IN, and
IVp are likely to pose different problems and this will affect
heir tractability. Nonetheless, it can be anticipated that affini-
ies will be improved if two or more weak binding ligands can
e covalently linked or, alternatively, if a reactive functional
roup can be incorporated into a given specific non-covalent
igand.
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